In this podcast Javier Cortes discusses the results of the randomized, double-blind, phase III KEYNOTE-355 trial. This trial demonstrated that pembrolizumab + chemotherapy resulted in a prolonged progression-free survival compared to placebo + chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
